LET-PTNCT07942363
Evaluating Clinical Impact of Linear Energy Transfer Distribution in Proton Therapy for Primary Brain Tumours
StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
The occurrence of Treatment-Related Imaging Abnormality (TRIA) CTCAE version 5.0 grade ≥ 1.
Timeframe: Up to 12 months after treatment. MRI at 6 and 12 months after completion of proton therapy treatment for assessment of TRIA.
Secondary (12)
Treatment planning feasibility: number of plan iterations.
Treatment planning feasibility: number of plans requiring LET-based replanning.
Treatment planning feasibility: planning effort
CNS toxicities
Quality of life assessments: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30).
Show 7 moreShow less
Quality of life assessments: European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire - Brain Neoplasm (20 items) (EORTC QLQ-BN20).
Quality of life assessments: Pediatric Quality of Life Inventory (PedsQL) Brain Tumor Module.
Response assessment
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Maximum LETd in healthy brain tissue.
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Maximum constant RBE-weighted dose in healthy brain tissue.
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Maximum variable RBE-weighted dose in healthy brain tissue.
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Target coverage.
Arms and interventions
LET-based evaluation in treatment planningExperimental
Radiation: Radiotherapy
Diagnostic tests: MRI
Other: Quality of Life (QoL) assessments., Toxicity scoring
Sites
1 site in 1 country
- UZ LeuvenLeuven, Belgium